We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cerebral Microdialysis in Patients With Fulminant Hepatic Failure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00836420
Recruitment Status : Completed
First Posted : February 4, 2009
Last Update Posted : October 27, 2015
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
Patients with fulminant hepatic failure (FHF) often develop cerebral edema, high intracranial pressure (ICP)that may result in fatal brain damage. The aim in this protocol is to determine if a rise in the brain concentration of glutamate, lactate and pyruvate are involved in development of surges of high ICP in patients with FHF. The study is observatory in nature and also record the influence of any intervention that may e instituted during the course of the critical illness.

Condition or disease Intervention/treatment
Fulminant Hepatic Failure Procedure: no intervention

Detailed Description:
Fulminant hepatic failure (FHF) is often complicated by cerebral edema, high intracranial pressure (ICP) and brain death. Accordingly the intracranial pressure is often monitored in such patients in order to be able to institute treatment before high ICP evolves. As routinely done in patients with severe head injury a microdialysis monitoring catheter is also placed under this procedure to measure metabolic changes that are responsible for surges of high ICP. The aim in this descriptive protocol is to determine if a rise in glutamate, lactate and pyruvate concentration in the brain cortex are involved in development of surges of high ICP in patients with FHF. The study is observatory in nature and also record the influence of any intervention during the course of the critical illness.

Study Design

Study Type : Observational
Actual Enrollment : 50 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Cerebral Microdialysis in Patients With Fulminant Hepatic Failure
Study Start Date : January 2000
Primary Completion Date : October 2015
Study Completion Date : October 2015
Groups and Cohorts

Group/Cohort Intervention/treatment
liver
patients with acute liver failure
Procedure: no intervention
the value of the clinical use of microdialysis monitoring of the brain


Outcome Measures

Primary Outcome Measures :
  1. Brain lactate concentration and intracranial hypertension [ Time Frame: 2013 ]
    to determine if brain oxidative metabolism correlates with brain edema and high intracranial pressure


Biospecimen Retention:   Samples Without DNA
microdialysate from the brain as part of rutine monitoring

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
consecutive patients with fulminant hepatic failure
Criteria

Inclusion Criteria:

  • All patients with fulminant hepatic failure

Exclusion Criteria:

  • Age below 18 years
  • Pregnancy
  • Not obtained informed consent
  • Suspicion of cancer disease
  • No pupil reaction to light
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00836420


Locations
Denmark
Rigshospitalet Dept Hepatology A-2121
Copenhagen, Denmark, 2100
Sponsors and Collaborators
Rigshospitalet, Denmark
Investigators
Study Chair: Fin Stolze Larsen Rigshospitalet, Denmark
More Information

Publications:
Responsible Party: Dr. Fin Stolze Larsen, consultant, Rigshospitalet, Denmark
ClinicalTrials.gov Identifier: NCT00836420     History of Changes
Other Study ID Numbers: KF 00/002
First Posted: February 4, 2009    Key Record Dates
Last Update Posted: October 27, 2015
Last Verified: October 2015

Keywords provided by Dr. Fin Stolze Larsen, Rigshospitalet, Denmark:
ammonia
acute liver failure
brain edema
oxidative metabolism
intracranial pressure

Additional relevant MeSH terms:
Liver Failure
Liver Failure, Acute
Hepatic Insufficiency
Liver Diseases
Digestive System Diseases